
Artificial intelligence (AI) in healthcare is no longer a futuristic idea. Organizations are benefiting-on administrative and clinical levels-from practical adoptions that make cost savings and better patient care a reality.

Artificial intelligence (AI) in healthcare is no longer a futuristic idea. Organizations are benefiting-on administrative and clinical levels-from practical adoptions that make cost savings and better patient care a reality.

When you are at the top or close to the peak in the leadership hierarchy, sometimes it’s hard to get proper advice. After all, with rank comes power, and many of your colleagues may be unwilling to speak the truth because they are protecting their own interests.

For many in healthcare, passion in the job comes from purpose, but sometimes, you may lose some of that fire. Here are some valuable tips from executive coaches that will help you rediscover that passion.

While we can’t help you cut down on your responsibilities, we can help you work more efficiently so that, hopefully, you won’t need to work so much.

Researchers and scientists continue to develop and test new treatments for these fatal conditions. Here’s a look at some major developments in these areas.


How healthcare executives can ensure they are always in the best position to take advantage of the next career opportunity.

From EHRs that didn’t fulfill promised savings to a system that still rewards volume over value, our experts examine what’s next in the quest to cut the fat from healthcare spending.

Managed Healthcare Executive asked key opinion leaders their thoughts on the drug rebate controversy. Here’s what they said.

FDA’s new guidance provides a roadmap for health executives on incorporating EHRs into clinical trials.

When it comes to promising areas in the treatment of lymphoma and other blood cancers, gene therapy may be at the top of the list. Here’s why.

Thinking out of the box leads to the best innovation sometimes. Here are lessons healthcare leaders say can be learned from other industries.

Artificial intelligence is about to do what we hoped to see technology do in the last decade for the health industry: Empower organizations and clinicians to improve the health, outcomes, and experience of care for more people in less time and at lower cost.

Two oncology practices have wish list items for payers. Find out what they are.

The 30-year old regulation is in desperate need of modernization to fall in line with the changing needs of healthcare.

A new survey from HealthMine reveals shocking findings about connecting with Medicare Advantage members who have chronic conditions.

FDA okayed iobenguane I 131 (Azedra, Progenics Pharmaceuticals) injection for IV use to treat rare tumors of the adrenal gland.

Managing members with chronic conditions is a complex, costly challenge for health plans. Using AI to combine real-time patient data and guideline-directed medical therapy can help.

There’s nothing wrong with wanting to get ahead and move up the career ladder, but sometimes, healthcare executives have trouble advancing their careers the way they’d like. Here are some tips from top executive coaches.

A survey from Imprivata has surprising findings about the magnitude of the patient matching problem.

Here’s how payers can build an action plan to directly address their Health Outcomes Survey and CAHPS Star measures, and thus impact their overall Ratings.

FDA recently approved the first and only complete darunavir-based single-tablet regiment to treat HIV-1 in treatment-naïve and certain virologically suppressed adults.


Although Kavanaugh's paper trail on health policy is not vast, it does include some intriguing clues about how he might rule on future cases. Find out more.

Are recent pharma price drops just a response to political pressure or will the momentum last? Managed Healthcare Executive asked industry experts, and here’s what they said.

The lifestyle and physical well-being of a number of Type 1 and Type 2 diabetics appears to have received a significant boost. Read more.

In this era of precision oncology and targeted therapies for cancer, it’s even more important to include different populations when doing clinical trials. Here are three effective strategies.

A breast cancer drug is the first approval from FDA in 2 new pilot programs that make the development and review of cancer drugs more efficient.
